埃博拉病毒病研究综述:疫情爆发及现状

Gebretadik Fa, Seifu Mf, Gelaw Bk
{"title":"埃博拉病毒病研究综述:疫情爆发及现状","authors":"Gebretadik Fa, Seifu Mf, Gelaw Bk","doi":"10.4172/2161-1165.1000204","DOIUrl":null,"url":null,"abstract":"Background : Ebola virus disease (EVD) is caused by Ebola viruses (EBOV), members of the group of hemorrhagic fevers and it is one of the most dangerous infection diseases with mortality rates up to 90%. Ebola was firstly described in 1976 and since then occurred sporadically in Central Africa. Till 2014, twenty four outbreaks were described, but the number of deaths not exceeding 300 per outbreak. As of May 20, 2015 the cumulative number, suspected, and laboratory-confirmed cases attributed to Ebola virus was 26, 969, including 11,135 deaths. Pathogenesis : Ebola Viruses do not replicate through cell division, but instead insert their own genetic sequencing into the deoxyribonucleic acid (DNA) of the host cell and subsequently hijack all cellular processes, including transcription and translation. In essence, the host cell becomes a factory of viral proteins. As new viral capsules are formed, they bud from the host cell, taking a part of the host cell’s outer membrane, thus cloaking themselves against detection by the host’s immune system. In some cases, the patient’s immune system can produce enough antibodies to defeat the infection. With EVD, the virus can often reproduce so rapidly that the immune system never catches up. Transmission : The natural reservoir of EBOV is believed to be bats, particularly  fruit  bats,  and  it  is  primarily  transmitted  between  humans  and  from  animals  to humans  through  body  fluids. Clinical presentation : Symptoms  of  EVD include  abrupt  onset  of  fever, myalgias,  and  headache  in  the  early  phase,  followed  by  vomiting,  diarrhea  and possible  progression  to  hemorrhagic  rash,  life-threatening  bleeding,  and  multi organ failure in the later phase. Treatment : There are no approved treatments or vaccines available for EVD until today; the mainstay of therapy is supportive care.  However, there are a bunch of therapeutic approaches on the track which could have the real impact on control and prevention of this global threat.  High fatality, combined with the absence of treatment and vaccination options, makes Ebola virus an important public health pathogen and biothreat pathogen of category A. Keywords: Ebola virus, Ebola virus disease, hemorrhagic fever, outbreak, epidemic, supportive care, reservoir, West Africa.","PeriodicalId":237804,"journal":{"name":"Journal of Pharmacy and Alternative Medicine","volume":"33 7-8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":"{\"title\":\"Review on Ebola Virus Disease: Its Outbreak and Current Status\",\"authors\":\"Gebretadik Fa, Seifu Mf, Gelaw Bk\",\"doi\":\"10.4172/2161-1165.1000204\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background : Ebola virus disease (EVD) is caused by Ebola viruses (EBOV), members of the group of hemorrhagic fevers and it is one of the most dangerous infection diseases with mortality rates up to 90%. Ebola was firstly described in 1976 and since then occurred sporadically in Central Africa. Till 2014, twenty four outbreaks were described, but the number of deaths not exceeding 300 per outbreak. As of May 20, 2015 the cumulative number, suspected, and laboratory-confirmed cases attributed to Ebola virus was 26, 969, including 11,135 deaths. Pathogenesis : Ebola Viruses do not replicate through cell division, but instead insert their own genetic sequencing into the deoxyribonucleic acid (DNA) of the host cell and subsequently hijack all cellular processes, including transcription and translation. In essence, the host cell becomes a factory of viral proteins. As new viral capsules are formed, they bud from the host cell, taking a part of the host cell’s outer membrane, thus cloaking themselves against detection by the host’s immune system. In some cases, the patient’s immune system can produce enough antibodies to defeat the infection. With EVD, the virus can often reproduce so rapidly that the immune system never catches up. Transmission : The natural reservoir of EBOV is believed to be bats, particularly  fruit  bats,  and  it  is  primarily  transmitted  between  humans  and  from  animals  to humans  through  body  fluids. Clinical presentation : Symptoms  of  EVD include  abrupt  onset  of  fever, myalgias,  and  headache  in  the  early  phase,  followed  by  vomiting,  diarrhea  and possible  progression  to  hemorrhagic  rash,  life-threatening  bleeding,  and  multi organ failure in the later phase. Treatment : There are no approved treatments or vaccines available for EVD until today; the mainstay of therapy is supportive care.  However, there are a bunch of therapeutic approaches on the track which could have the real impact on control and prevention of this global threat.  High fatality, combined with the absence of treatment and vaccination options, makes Ebola virus an important public health pathogen and biothreat pathogen of category A. Keywords: Ebola virus, Ebola virus disease, hemorrhagic fever, outbreak, epidemic, supportive care, reservoir, West Africa.\",\"PeriodicalId\":237804,\"journal\":{\"name\":\"Journal of Pharmacy and Alternative Medicine\",\"volume\":\"33 7-8 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy and Alternative Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2161-1165.1000204\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Alternative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2161-1165.1000204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

摘要

背景:埃博拉病毒病(EVD)是由出血热科成员埃博拉病毒(EBOV)引起的,是最危险的传染病之一,死亡率高达90%。埃博拉病毒于1976年首次被描述,此后在中非零星发生。截至2014年,共发生了24次暴发,但每次暴发的死亡人数不超过300人。截至2015年5月20日,由埃博拉病毒引起的疑似病例和实验室确诊病例累计数为26,969例,包括11135例死亡。发病机制:埃博拉病毒不通过细胞分裂进行复制,而是将自己的基因序列插入宿主细胞的脱氧核糖核酸(DNA)中,随后劫持包括转录和翻译在内的所有细胞过程。从本质上讲,宿主细胞变成了病毒蛋白质的工厂。当新的病毒囊形成时,它们从宿主细胞中发芽,占据宿主细胞外膜的一部分,从而使自己隐藏起来,不被宿主的免疫系统发现。在某些情况下,病人的免疫系统可以产生足够的抗体来战胜感染。对于埃博拉病毒病,病毒通常可以快速繁殖,以至于免疫系统永远赶不上。传播:据信埃博拉病毒的天然宿主是蝙蝠,特别是果蝠,它主要在人与人之间传播,并通过体液从动物传播到人。临床表现:埃博拉病毒病的症状包括早期突发性发热、肌痛和头痛,随后出现呕吐、腹泻,后期可能发展为出血性皮疹、危及生命的出血和多器官衰竭。治疗:迄今为止,尚无针对埃博拉病毒病的批准治疗方法或疫苗;治疗的主要方法是支持性护理。然而,目前有很多治疗方法可以对控制和预防这一全球威胁产生真正的影响。高致死率,加上缺乏治疗和疫苗接种方案,使埃博拉病毒成为重要的公共卫生病原体和a类生物威胁病原体。关键词:埃博拉病毒,埃博拉病毒病,出血热,暴发,流行,支持性护理,水库,西非。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Review on Ebola Virus Disease: Its Outbreak and Current Status
Background : Ebola virus disease (EVD) is caused by Ebola viruses (EBOV), members of the group of hemorrhagic fevers and it is one of the most dangerous infection diseases with mortality rates up to 90%. Ebola was firstly described in 1976 and since then occurred sporadically in Central Africa. Till 2014, twenty four outbreaks were described, but the number of deaths not exceeding 300 per outbreak. As of May 20, 2015 the cumulative number, suspected, and laboratory-confirmed cases attributed to Ebola virus was 26, 969, including 11,135 deaths. Pathogenesis : Ebola Viruses do not replicate through cell division, but instead insert their own genetic sequencing into the deoxyribonucleic acid (DNA) of the host cell and subsequently hijack all cellular processes, including transcription and translation. In essence, the host cell becomes a factory of viral proteins. As new viral capsules are formed, they bud from the host cell, taking a part of the host cell’s outer membrane, thus cloaking themselves against detection by the host’s immune system. In some cases, the patient’s immune system can produce enough antibodies to defeat the infection. With EVD, the virus can often reproduce so rapidly that the immune system never catches up. Transmission : The natural reservoir of EBOV is believed to be bats, particularly  fruit  bats,  and  it  is  primarily  transmitted  between  humans  and  from  animals  to humans  through  body  fluids. Clinical presentation : Symptoms  of  EVD include  abrupt  onset  of  fever, myalgias,  and  headache  in  the  early  phase,  followed  by  vomiting,  diarrhea  and possible  progression  to  hemorrhagic  rash,  life-threatening  bleeding,  and  multi organ failure in the later phase. Treatment : There are no approved treatments or vaccines available for EVD until today; the mainstay of therapy is supportive care.  However, there are a bunch of therapeutic approaches on the track which could have the real impact on control and prevention of this global threat.  High fatality, combined with the absence of treatment and vaccination options, makes Ebola virus an important public health pathogen and biothreat pathogen of category A. Keywords: Ebola virus, Ebola virus disease, hemorrhagic fever, outbreak, epidemic, supportive care, reservoir, West Africa.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Indirect Heamagglutination as An Immunodiagnostic Technique For Cystic Echinococcosis In Iraqi Patients Review on Ebola Virus Disease: Its Outbreak and Current Status Prescription Pattern of Injection at Out Patient Pharmacy Department of Adama Hospital Medical College, Adama,
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1